In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:

• TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan 
• TROP2 ADCS for patients with EGFR-mutated NSCLC
• TIGIT-targeting agents: domvanalimab, rilvegostomig

Presenters:

Benjamin Levy, MD, FASCO
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)
Washington, DC

Alex Spira, MD, PhD, FASCO
Director Clinical Research
Virginia Cancer Specialists
CEO NEXT Oncology Virginia
Fairfax, Virginia

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/4qZLR6B

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:

• Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection
• The recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)
• Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEON
   

Presenters:
Rachel Grisham, MD
Section Head of Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Director Gynecologic Medical Oncology, MSKCC Westchester
New York, New York

Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:

• Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer
• Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease
• How R-DXd may be incorporated into the treatment paradigm
• Other investigational CDH6-targeting ADCs: CUSP06, SIM0505

Presenters:

Kathleen N. Moore, MD, MS, FASCO 
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma

Isabelle Ray-Coquard, MD, PhD 
President of the Gineco Group
Centre Leon Bérard
Reshape Lab Inserm u1290
Université Claude Bernard Lyon Est
Lyon, France

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program: 
https://bit.ly/43PXoeP

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including:

• Trials of neoadjuvant immunotherapies demonstrating remarkable response rates with PD-(L)1 inhibitors such as cemiplimab, pembrolizumab, atezolizumab, and nivolumab with or without ipilimumab
• Ongoing investigational efforts, including the phase III CLEAR CSCC study of intralesional immunotherapy and radiation-immunotherapy sequencing

Presenters:

David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, Massachusetts

Vishal Anil Patel, MD
Director of Cutaneous Oncology, GW Cancer Center
Director of Dermatologic Surgery, GW Department of Dermatology
Associate Professor of Dermatology & of Medicine (Hematology/Oncology)
George Washington University School of Medicine & Health Sciences
Washington, DC

Link to full program: 
https://bit.ly/3JbflO3

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:

• The pathogenesis of PNH and the role of complement activation
• Landmark therapies such as eculizumab and ravulizumab
• Advances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)
• Quality-of-life considerations, treatment personalization, and emerging therapies

Presenters:

Carlos M. De Castro, MD
Professor of Medicine, DUMC
Division of Malignant Hematology and Cellular Therapy
Department of Medicine
Duke University
Duke Cancer Institute
Durham, North Carolina

David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath
Consultant Hematologist and Director of Bone Marrow Transplant Program
Professor of Medicine
Division of Hematology
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Link to full program:
https://bit.ly/3Jtjqgr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on how to personalize adjuvant therapy for these patients. Supported by an educational grant from Lilly.

Faculty:

Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Erin F. Cobain, MD
Associate Professor of Internal Medicine
Division of Hematology/Oncology
Breast Oncology Program
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan 

Link to obtain CME/CE credit: 
https://bit.ly/46RvtgH

Link to Oncology Breast Cancers with additional educational activities: 
https://bit.ly/4h7R3AO

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy for these patients. Supported by an educational grant from Lilly.

Faculty:

Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Erin F. Cobain, MD
Associate Professor of Internal Medicine
Division of Hematology/Oncology
Breast Oncology Program
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan 

Link to obtain CME/CE credit:
https://bit.ly/4nUJO1O

Link to Oncology Breast Cancers with additional educational activities:
https://bit.ly/4nNGlBY

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:

• Brief overview of BTC and GEA
• Approved HER2-directed therapies for BTC and GEA and their mechanisms of action
• Efficacy and toxicities of the approved agents and optimal management strategies
• Key ongoing trials of HER2-directed therapies in BTC and GEA
• Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA 

Presenters

Amit Mahipal, MD, MPH
Director, Gastrointestinal Medical Oncology Program
Ruth and Donald Goodman Endowed Chair in GI Oncology
Professor of Medicine, Senior Attending Physician
University Hospitals Siedman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Shubham Pant, MD
Professor
Department of Gastrointestinal (GI) Medical Oncology
Department of Investigational Cancer Therapeutics
Director of Clinical Research
Associate Director for Early Phase Drug Development
Sheikh Ahmed Bin Zayed Al Nahyan Center
MD Anderson Cancer Center
Houston, Texas

Link to full program:
https://bit.ly/3KL2ank

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:

• Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamab
• Monitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma 
• Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamig

Presenters: 

Dr Christopher Flowers 
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Dr John Allan
Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Content based on an online CME program supported by Regeneron Pharmaceuticals, Inc.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including:

• How patients often present with disease-related symptoms
• Treatment selection considerations for the first-line and second-line setting
• How to approach palliative care discussions with patients
• Emerging therapies that are showing promise in this setting

Presenters

Paul E. Oberstein, MD
Associate Professor of Medicine
Section Chief, GI Oncology
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Mark O’Hara, MD
Associate Professor of Medicine
Division of Hematology and Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Link to full program: 
https://bit.ly/45NdBTx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.